Skip to main content
EJNMMI Research

Table 1 The extent of metastases and history of chemotherapy in ten patients with prostate cancer

From: Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Number

Age (y/o)

Metastases

History of CTx

Dose GBq

1

70

Bone3, Ln1, LR

No

5.8

2

77

Bone3, LR

Yes

6.1

3

67

Bone3, Ln1, LR

Yes

6.0

4

75

Bone3, Ln1

No

5.9

5

77

Bone3, Ln2

No

4.1

6

81

Bone3, Ln1

No

5.9

7

62

Ln2

Yes

5.8

8

74

Ln2, liver met

Yes

5.7

9

76

Bone1, Ln1,

Yes

5.8

10

76

Bone3, Ln1

No

5.2

  1. Bone1 <6 bone metastases, bone2 6–20 bone metastases, bone3 >20 bone metastases
  2. Ln1 lymph node metastasis (abdominal, iliacal and inguinal), Ln2 Ln1 + thoracal lymph node metastasis, LR local recurrence, CTx chemotherapy
Back to article page